Failure to thrive: A severe manifestation of interleukin 10 receptor A mutation in adult inflammatory bowel disease

2021 ◽  
Author(s):  
Nicole C. Ruiz ◽  
Amir Y. Kamel ◽  
Xiuli Liu ◽  
Angela Pham ◽  
Christopher Forsmark ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Failure To Thrive ◽  
Interleukin 10 ◽  
Severe Manifestation ◽  
Inflammatory Bowel

Association between polymorphisms in the promoter region of interleukin-10 and susceptibility to inflammatory bowel disease

2014 ◽  
Vol 41 (3) ◽  
pp. 1299-1310 ◽  
Author(s):  
Hongchao Lv ◽  
Yongshuai Jiang ◽  
Jin Li ◽  
Mingming Zhang ◽  
Zhenwei Shang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Promoter Region ◽  
Interleukin 10 ◽  
Inflammatory Bowel

scholarly journals Alterations of Colonic Contractility in an Interleukin-10 Knockout Mouse Model of Inflammatory Bowel Disease

2015 ◽  
Vol 21 (1) ◽  
pp. 051-061 ◽  
Author(s):  
Jae Hyung Park ◽  
Joong Goo Kwon ◽  
Sun Joo Kim ◽  
Dae Kyu Song ◽  
Seok Guen Lee ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Mouse Model ◽  
Bowel Disease ◽  
Knockout Mouse ◽  
Interleukin 10 ◽  
Knockout Mouse Model ◽  
Inflammatory Bowel

scholarly journals Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse — A model mimicking inflammatory bowel disease

2014 ◽  
Vol 8 (2) ◽  
pp. 147-160 ◽  
Author(s):  
Kristine Holgersen ◽  
Peter Helding Kvist ◽  
Helle Markholst ◽  
Axel Kornerup Hansen ◽  
Thomas Lindebo Holm
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Interleukin 10 ◽  
Knock Out ◽  
Inflammatory Bowel ◽  
Knock Out Mouse

Interleukin-10 and Interleukin-10–Receptor Defects in Inflammatory Bowel Disease

2012 ◽  
Vol 12 (5) ◽  
pp. 373-379 ◽  
Author(s):  
Neil Shah ◽  
Jochen Kammermeier ◽  
Mamoun Elawad ◽  
Erik-Oliver Glocker
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Interleukin 10 ◽  
Inflammatory Bowel

scholarly journals Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 397 ◽  
Author(s):  
Paolo Giuffrida ◽  
Sara Cococcia ◽  
Mariangela Delliponti ◽  
Marco Vincenzo Lenti ◽  
Antonio Di Sabatino
Keyword(s):  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Bowel Disease ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interleukin 10 ◽  
Interleukin 12 ◽  
Inflammatory Pathways ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Inflammatory bowel disease (IBD) is caused by a dysregulated immune response against normal components of the intestinal microflora combined with defective functioning of anti-inflammatory pathways. Currently, all therapies approved for IBD manipulate the immune system by inhibiting pro-inflammatory mechanisms, such as tumor necrosis factor-α, gut-homing α4β7 integrin, interleukin-12/interleukin-23, and Janus kinases. However, some IBD patients are non-responders to these drugs, which are also associated with serious side effects. Thus, it has been hypothesized that therapies aimed at restoring anti-inflammatory signals, by exploiting the tolerogenic potential of cytokines (interleukin-10, transforming growth factor-β, granulocyte macrophage colony-stimulating factor), immune cells (regulatory T cells, tolerogenic dendritic cells), or mesenchymal stem cells, might offer promising results in terms of clinical efficacy with fewer side effects. In this review, we provide new insights into putative novel treatments aimed at restoring anti-inflammatory signaling pathways in IBD.

Sign in / Sign up

Export Citation Format

Share Document